839 related articles for article (PubMed ID: 31005275)
1. Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients.
Lefaucheur C; Viglietti D; Bouatou Y; Philippe A; Pievani D; Aubert O; Duong Van Huyen JP; Taupin JL; Glotz D; Legendre C; Loupy A; Halloran PF; Dragun D
Kidney Int; 2019 Jul; 96(1):189-201. PubMed ID: 31005275
[TBL] [Abstract][Full Text] [Related]
2. Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis.
Gosset C; Viglietti D; Rabant M; Vérine J; Aubert O; Glotz D; Legendre C; Taupin JL; Duong Van-Huyen JP; Loupy A; Lefaucheur C
Kidney Int; 2017 Sep; 92(3):729-742. PubMed ID: 28554738
[TBL] [Abstract][Full Text] [Related]
3. Investigation of Serum Angiotensin II Type 1 Receptor Antibodies at the Time of Renal Allograft Rejection.
Lee H; Kim JI; Moon IS; Chung BH; Yang CW; Kim Y; Han K; Oh EJ
Ann Lab Med; 2015 May; 35(3):314-20. PubMed ID: 25932439
[TBL] [Abstract][Full Text] [Related]
4. ARHGDIB and AT1R autoantibodies are differentially related to the development and presence of chronic antibody-mediated rejection and fibrosis in kidney allografts.
Betjes MGH; Sablik KA; Litjens NHR; Otten HG; de Weerd AE
Hum Immunol; 2021 Feb; 82(2):89-96. PubMed ID: 33358038
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Antibodies Directed Against Two GPCRs, Anti-AT1R and Anti-ETAR, on Kidney Transplant Outcome.
El Band JEK; Llorente S; Martinez-Garcia P; Alfaro R; Jimenez-Coll V; Boix F; Galián JA; Martinez-Banaclocha H; Botella C; Moya-Quiles MR; Minguela A; Legaz I; Muro M
Curr Protein Pept Sci; 2021; 22(10):745-757. PubMed ID: 34967284
[TBL] [Abstract][Full Text] [Related]
6. Clinical Impact of Pre-transplant Antibodies Against Angiotensin II Type I Receptor and Major Histocompatibility Complex Class I-Related Chain A in Kidney Transplant Patients.
Min JW; Lee H; Choi BS; Park CW; Yang CW; Kim YS; Choi YJ; Oh EJ; Chung BH
Ann Lab Med; 2018 Sep; 38(5):450-457. PubMed ID: 29797816
[TBL] [Abstract][Full Text] [Related]
7. Anti-Angiotensin II Type 1 Receptor and Anti-Endothelial Cell Antibodies: A Cross-Sectional Analysis of Pathological Findings in Allograft Biopsies.
Philogene MC; Bagnasco S; Kraus ES; Montgomery RA; Dragun D; Leffell MS; Zachary AA; Jackson AM
Transplantation; 2017 Mar; 101(3):608-615. PubMed ID: 27222934
[TBL] [Abstract][Full Text] [Related]
8. The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes.
Banasik M; Boratyńska M; Kościelska-Kasprzak K; Kamińska D; Bartoszek D; Zabińska M; Myszka M; Zmonarski S; Protasiewicz M; Nowakowska B; Hałoń A; Chudoba P; Klinger M
Transpl Int; 2014 Oct; 27(10):1029-38. PubMed ID: 24909812
[TBL] [Abstract][Full Text] [Related]
9. Association of angiotensin II type 1 receptor antibodies with graft histology, function and survival in paediatric renal transplant recipients.
Fichtner A; Süsal C; Schröder C; Höcker B; Rieger S; Waldherr R; Westhoff JH; Sander A; Dragun D; Tönshoff B
Nephrol Dial Transplant; 2018 Jun; 33(6):1065-1072. PubMed ID: 29444269
[TBL] [Abstract][Full Text] [Related]
10. Histopathologic changes in anti-angiotensin II type 1 receptor antibody-positive kidney transplant recipients with acute rejection and no donor specific HLA antibodies.
Lim MA; Palmer M; Trofe-Clark J; Bloom RD; Jackson A; Philogene MC; Kamoun M
Hum Immunol; 2017 Apr; 78(4):350-356. PubMed ID: 28284829
[TBL] [Abstract][Full Text] [Related]
11. Antibody-Mediated Rejection in Kidney Transplantation Without Evidence of Anti-HLA Antibodies?
Irure J; López-Hoyos M; Rodrigo E; Gómez-Román J; Ruiz JC; Arias M; San Segundo D
Transplant Proc; 2016 Nov; 48(9):2888-2890. PubMed ID: 27932099
[TBL] [Abstract][Full Text] [Related]
12. Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment.
Lefaucheur C; Viglietti D; Hidalgo LG; Ratner LE; Bagnasco SM; Batal I; Aubert O; Orandi BJ; Oppenheimer F; Bestard O; Rigotti P; Reisaeter AV; Kamar N; Lebranchu Y; Duong Van Huyen JP; Bruneval P; Glotz D; Legendre C; Empana JP; Jouven X; Segev DL; Montgomery RA; Zeevi A; Halloran PF; Loupy A
J Am Soc Nephrol; 2018 Feb; 29(2):620-635. PubMed ID: 29042454
[TBL] [Abstract][Full Text] [Related]
13. Non-HLA antibodies: angiotensin II type 1 receptor (anti-AT1R) and endothelin-1 type A receptor (anti-ETAR) are associated with renal allograft injury and graft loss.
Banasik M; Boratyńska M; Kościelska-Kasprzak K; Kamińska D; Zmonarski S; Mazanowska O; Krajewska M; Bartoszek D; Zabińska M; Myszka M; Kamińska M; Hałoń A; Dawiskiba T; Szyber P; Sas A; Klinger M
Transplant Proc; 2014 Oct; 46(8):2618-21. PubMed ID: 25380879
[TBL] [Abstract][Full Text] [Related]
14. Post-transplant donor specific antibody is associated with poor kidney transplant outcomes only when combined with both T-cell-mediated rejection and non-adherence.
Cherukuri A; Mehta R; Sharma A; Sood P; Zeevi A; Tevar AD; Rothstein DM; Hariharan S
Kidney Int; 2019 Jul; 96(1):202-213. PubMed ID: 31029504
[TBL] [Abstract][Full Text] [Related]
15. Deleterious effect of anti-angiotensin II type 1 receptor antibodies detected pretransplant on kidney graft outcomes is both proper and synergistic with donor-specific anti-HLA antibodies.
Malheiro J; Tafulo S; Dias L; Martins S; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
Nephrology (Carlton); 2019 Mar; 24(3):347-356. PubMed ID: 29451342
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin II Type 1 receptor antibodies are associated with inflammatory cytokines and poor clinical outcomes in pediatric kidney transplantation.
Pearl MH; Zhang Q; Palma Diaz MF; Grotts J; Rossetti M; Elashoff D; Gjertson DW; Weng P; Reed EF; Tsai Chambers E
Kidney Int; 2018 Jan; 93(1):260-269. PubMed ID: 28927645
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients.
Lee H; Han E; Choi AR; Ban TH; Chung BH; Yang CW; Choi YJ; Oh EJ
PLoS One; 2018; 13(11):e0207434. PubMed ID: 30427941
[TBL] [Abstract][Full Text] [Related]
18. Successful Treatment of Anti-angiotensin II Type 1 Receptor Antibody-Associated Rejection in Kidney Transplantation: A Case Report.
Wiwattanathum P; Ingsathit A; Thammanichanond D; Worawichawong S
Transplant Proc; 2018 Apr; 50(3):877-880. PubMed ID: 29331505
[TBL] [Abstract][Full Text] [Related]
19. C4d-negative antibody-mediated rejection with high anti-angiotensin II type I receptor antibodies in absence of donor-specific antibodies.
Fuss A; Hope CM; Deayton S; Bennett GD; Holdsworth R; Carroll RP; Coates PT
Nephrology (Carlton); 2015 Jul; 20(7):467-73. PubMed ID: 25726938
[TBL] [Abstract][Full Text] [Related]
20. Levels of angiotensin II type-1 receptor antibodies and endothelin-1 type-A receptor antibodies correlate with antibody-mediated rejection and poor graft function in kidney-transplantation patients.
Liu C; Kang ZY; Yin Z; Xiao Y; Liu W; Zhao Y; Li DH
Transpl Immunol; 2022 Oct; 74():101674. PubMed ID: 35901953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
